Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve Silber

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
American Journal of Disaster Medicine|February 15, 2008
Activating physicians within a hospital emergency plan: a concept whose time has come?Kristine M Gebbie, Steve Silber, Michael McCollum, et al.
Journal of Clinical Psychopharmacology|May 15, 2009
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation studyLenard A Adler, Brenda Zimmerman, H Lynn Starr, et al.
Journal of Clinical Psychopharmacology|December 31, 2010
Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year studyLenard A Adler, Camille Orman, H Lynn Starr, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
American Journal of Disaster Medicine|February 15, 2008
Activating physicians within a hospital emergency plan: a concept whose time has come?Kristine M Gebbie, Steve Silber, Michael McCollum, et al.
Journal of Clinical Psychopharmacology|May 15, 2009
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation studyLenard A Adler, Brenda Zimmerman, H Lynn Starr, et al.
Journal of Clinical Psychopharmacology|December 31, 2010
Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year studyLenard A Adler, Camille Orman, H Lynn Starr, et al.
Pageof 1